Table 2.
Human clinical trials focusing on aging.
| Flavonoid Therapy | Indication | Dose and Duration | Trial |
|---|---|---|---|
| Quercetin (Q) + Dasatinib (D) | Alzheimer’s disease | Q (1000 mg/day) + D (100 mg/day) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles | NCT04785300 |
| Intermittent D + Q administered for 2 days on/14 days off for 12 weeks (6 cycles) | NCT04063124 | ||
| Age-related osteoporosis | D (100 mg/2 days) plus Q (1000 mg/day last for 3 days) taken orally on an intermittent schedule (starting every 28 days) over 20 weeks, resulting in five total dosing periods throughout the entire intervention | NCT04313634 | |
| Accelerated-ageing-like state post bone marrow transplantation |
Q (1000 mg/day) + D (100 mg/day) administered orally for 3 consecutive days | NCT02652052 | |
| Diabetic kidney disease | Q (1000 mg/day) + D (100 mg/day) administered orally for 3 consecutive days | NCT02848131 | |
| Epigenetic aging | 500 mg Q and 50 mg D oral capsules on Monday, Tuesday, and Wednesday (3 days in a row) for 6 months | NCT04946383 | |
| Fisetin | Age-related osteoporosis | 20 mg/kg/day for three consecutive days, taken orally on an intermittent schedule (starting every 28 days) over 20 weeks, resulting in five total dosing periods throughout the entire intervention | NCT04313634 |
| Elderly syndrome | 20 mg/kg/day, orally for 2 consecutive days | NCT03675724 | |
| Elderly syndrome in old women | 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months | NCT03430037 | |
| Osteoarthritis | Administered orally at 20 mg/kg for 2 consecutive days, followed by 28 days off, then 2 more consecutive days | NCT04210986 | |
| Oral fisetin 20 mg/kg taken for 10 days total | NCT04815902 | ||
| Diabetic and chronic kidney disease | 20 mg/kg/day, orally for 2 consecutive days | NCT03325322 | |
| COVID-19 in hospitalized patients | 20 mg/kg/day, orally for 2 consecutive days | NCT04476953 | |
| COVID-19 in outpatients | 20 mg/kg/day oral for 4 days | NCT04771611 | |
| Coronavirus disease 2019 (COVID-19) in nursing home patients | 20 mg/kg/day, orally for 2 consecutive days | NCT04537299 | |
| Genistein | Alzheimer’s disease | 60 mg of genistein BID for 360 days | NCT01982578 |
| Metabolic syndrome | Genistein capsules of 25 mg each, 50 mg/day | NCT04105023 | |
| Rutin | Type 2 diabetes mellitus | Rutin 60 mg in combination with vitamin C 160 mg three times daily in addition to usual antidiabetic treatment for 8 weeks. | NCT03437902 |